Clinical characteristics of the patients with MM included in the study
| Clinical data . | scATAC- and scRNA-seq . | scDNA-seq . | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Patient ID . | Sex . | Age (y) . | MM subtype . | t(11;14) status . | t(4;14) status . | t(14;16) status . | del13q status . | del17p status . | Stage (R-ISS) . | Number of prior therapies . | Best response to venetoclax . | Duration of response to venetoclax (mo) . | Prevenetoclax Sample . | Postvenetoclax Sample . | Prevenetoclax Sample . | Postvenetoclax Sample . |
| PM01 | M | 44 | IgGκ | Positive (17% of the cells) | Negative | Negative | Negative | Negative | II | 4 | VGPR | 8 | P1393 | P1555 | P1426 | P1555 |
| PM02 | M | 74 | IgGκ | Negative | Negative | Negative | Negative | Negative | I | 7 | NA | NA | P1723 | NA | NA | NA |
| PM03 | F | 66 | κ light chain | Negative | Negative | Negative | Negative | Negative | III | 4 | NA | NA | P1608 | P1675 | NA | NA |
| PM04 | F | 82 | IgGκ | Negative | Negative | Negative | Negative | Negative | II | 3 | NA | NA | P1299 | P1345 | NA | NA |
| PM05 | M | 78 | Λ light chain | Positive (97% of the cells) | Negative | Negative | Negative | Positive (99% of cells) | II | 8 | VGPR | 21 | P1643 | NA | NA | NA |
| PM06 | M | 65 | IgGκ | Negative | Negative | Negative | Negative | Negative | III | 4 | NA | NA | P1752 | NA | NA | NA |
| PM07 | M | 69 | IgGλ | Positive (88% of the cells) | Negative | Negative | Negative | Positive (66% of cells) | I | 4 | PR | 4 | P1389 | P1479 | P1389 | P1479 |
| PM08 | M | 60 | IgAκ | Negative | Positive (17% of the cells) | Negative | Negative | Negative | II | 6 | NA | NA | P1680 | NA | NA | NA |
| PM09 | M | 74 | IgGλ | Positive (77% of the cells) | Negative | Negative | Negative | Negative | I | 4 | VGPR | 13 | P1498 | P1698 | P1498 | P1698 |
| PM10 | F | 61 | IgGλ | Positive (94% of the cells) | Negative | Negative | Negative | Negative | II | 10 | VGPR | 11 | P1217 | P1438 | P1217 | P1438 |
| PM11 | F | 84 | IgAλ | Positive (49% of the cells) | Negative | Negative | Negative | Negative | III | 3 | VGPR | 38 | P1388 | NA | NA | NA |
| PM12 | M | 66 | IgGλ | Negative | Negative | Negative | Negative | Negative | I | 4 | NA | NA | P1751 | P1809 | NA | NA |
| PM13 | M | 81 | IgAκ | Negative | Negative | Negative | Negative | Negative | III | 1 | NA | NA | P1396 | P1461 | NA | NA |
| PM14 | F | 70 | IgAλ and IgGλ | Negative | Negative | Negative | Negative | Negative | II | 2 | NA | NA | P1395 | P1606 | NA | NA |
| PM15 | M | 60 | IgAκ | Negative | Negative | Negative | Negative | Negative | II | 2 | NA | NA | P1722 | NA | NA | NA |
| Clinical data . | scATAC- and scRNA-seq . | scDNA-seq . | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Patient ID . | Sex . | Age (y) . | MM subtype . | t(11;14) status . | t(4;14) status . | t(14;16) status . | del13q status . | del17p status . | Stage (R-ISS) . | Number of prior therapies . | Best response to venetoclax . | Duration of response to venetoclax (mo) . | Prevenetoclax Sample . | Postvenetoclax Sample . | Prevenetoclax Sample . | Postvenetoclax Sample . |
| PM01 | M | 44 | IgGκ | Positive (17% of the cells) | Negative | Negative | Negative | Negative | II | 4 | VGPR | 8 | P1393 | P1555 | P1426 | P1555 |
| PM02 | M | 74 | IgGκ | Negative | Negative | Negative | Negative | Negative | I | 7 | NA | NA | P1723 | NA | NA | NA |
| PM03 | F | 66 | κ light chain | Negative | Negative | Negative | Negative | Negative | III | 4 | NA | NA | P1608 | P1675 | NA | NA |
| PM04 | F | 82 | IgGκ | Negative | Negative | Negative | Negative | Negative | II | 3 | NA | NA | P1299 | P1345 | NA | NA |
| PM05 | M | 78 | Λ light chain | Positive (97% of the cells) | Negative | Negative | Negative | Positive (99% of cells) | II | 8 | VGPR | 21 | P1643 | NA | NA | NA |
| PM06 | M | 65 | IgGκ | Negative | Negative | Negative | Negative | Negative | III | 4 | NA | NA | P1752 | NA | NA | NA |
| PM07 | M | 69 | IgGλ | Positive (88% of the cells) | Negative | Negative | Negative | Positive (66% of cells) | I | 4 | PR | 4 | P1389 | P1479 | P1389 | P1479 |
| PM08 | M | 60 | IgAκ | Negative | Positive (17% of the cells) | Negative | Negative | Negative | II | 6 | NA | NA | P1680 | NA | NA | NA |
| PM09 | M | 74 | IgGλ | Positive (77% of the cells) | Negative | Negative | Negative | Negative | I | 4 | VGPR | 13 | P1498 | P1698 | P1498 | P1698 |
| PM10 | F | 61 | IgGλ | Positive (94% of the cells) | Negative | Negative | Negative | Negative | II | 10 | VGPR | 11 | P1217 | P1438 | P1217 | P1438 |
| PM11 | F | 84 | IgAλ | Positive (49% of the cells) | Negative | Negative | Negative | Negative | III | 3 | VGPR | 38 | P1388 | NA | NA | NA |
| PM12 | M | 66 | IgGλ | Negative | Negative | Negative | Negative | Negative | I | 4 | NA | NA | P1751 | P1809 | NA | NA |
| PM13 | M | 81 | IgAκ | Negative | Negative | Negative | Negative | Negative | III | 1 | NA | NA | P1396 | P1461 | NA | NA |
| PM14 | F | 70 | IgAλ and IgGλ | Negative | Negative | Negative | Negative | Negative | II | 2 | NA | NA | P1395 | P1606 | NA | NA |
| PM15 | M | 60 | IgAκ | Negative | Negative | Negative | Negative | Negative | II | 2 | NA | NA | P1722 | NA | NA | NA |
Cytogenetic abnormalities identified based on fluorescence in situ hybridization in this patient cohort; R-ISS (revised international staging system); VGPR (very good partial response); PR (partial response); SD (stable disease); MR (minimal response); and duration of response to venetoclax.
F, female; ID, identification number; Ig, immunoglobulin; M, male; NA, not available.